Hanmi Pharmaceutical announced on the 14th that it has confirmed cases of complete response (CR) in various dose groups as a result of phase 1/2 clinical trials of Tuspetinib (HM43239), which is being developed as an AML treatment. Aptose was recently introduced at the KOL webinar, "As a result of the global phase 1/2 for patients with recurrent or refractory acute myeloid leukemia, we confirmed CR cases in all of the various doses (80 mg, 120 mg, 160 mg) of HM43239." Aptose will present details of the study at the 64th ASH in New Orleans, the U.S., from the 10th to the 13th of next month. HM43239 is an oral MKI administered once a day that targets major kinases acting in myelogenous malignant tumors. It was designate